Literature DB >> 19150509

PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice.

Willeke de Haan1, Jitske de Vries-van der Weij, Isabel M Mol, Menno Hoekstra, Johannes A Romijn, J Wouter Jukema, Louis M Havekes, Hans M G Princen, Patrick C N Rensen.   

Abstract

Pregnane X receptor (PXR) agonism has been shown to affect multiple steps in both the synthesis and catabolism of HDL, but its integrated effect on HDL metabolism in vivo remains unclear. The aim of this study was to evaluate the net effect of PXR agonism on HDL metabolism in ApoE3-Leiden (E3L) and E3L.CETP mice, well-established models for human-like lipoprotein metabolism. Female mice were fed a diet with increasing amounts of the potent PXR agonist 5-pregnen-3beta-ol-20-one-16alpha-carbonitrile (PCN). In E3L and E3L.CETP mice, PCN increased liver lipids as well as plasma cholesterol and triglycerides. However, whereas PCN increased cholesterol contained in large HDL-1 particles in E3L mice, it dose-dependently decreased HDL-cholesterol in E3L.CETP mice, indicating that CETP expression dominates the effect of PCN on HDL metabolism. Analysis of the hepatic expression of genes involved in HDL metabolism showed that PCN decreased expression of genes involved in HDL synthesis (Abca1, Apoa1), maturation (Lcat, Pltp) and clearance (Sr-b1). The HDL-increasing effect of PCN, observed in E3L mice, is likely caused by a marked decrease in hepatic SR-BI protein expression, and completely reversed by CETP expression. We conclude that chronic PXR agonism dose-dependently reduces plasma HDL-cholesterol in the presence of CETP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19150509     DOI: 10.1016/j.bbalip.2008.12.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

1.  Intestinal pregnane X receptor links xenobiotic exposure and hypercholesterolemia.

Authors:  Yipeng Sui; Robert N Helsley; Se-Hyung Park; Xiulong Song; Zun Liu; Changcheng Zhou
Journal:  Mol Endocrinol       Date:  2015-03-26

Review 2.  Novel functions of PXR in cardiometabolic disease.

Authors:  Changcheng Zhou
Journal:  Biochim Biophys Acta       Date:  2016-02-26

3.  Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis.

Authors:  Taesik Gwag; Zhaojie Meng; Yipeng Sui; Robert N Helsley; Se-Hyung Park; Shuxia Wang; Richard N Greenberg; Changcheng Zhou
Journal:  J Hepatol       Date:  2019-01-21       Impact factor: 25.083

4.  Deficiency of PXR decreases atherosclerosis in apoE-deficient mice.

Authors:  Yipeng Sui; Jinxian Xu; Jennifer Rios-Pilier; Changcheng Zhou
Journal:  J Lipid Res       Date:  2011-06-18       Impact factor: 5.922

5.  The atypical antipsychotic quetiapine induces hyperlipidemia by activating intestinal PXR signaling.

Authors:  Zhaojie Meng; Taesik Gwag; Yipeng Sui; Se-Hyung Park; Xiangping Zhou; Changcheng Zhou
Journal:  JCI Insight       Date:  2019-02-07

6.  Regulation of tissue-specific carboxylesterase expression by pregnane x receptor and constitutive androstane receptor.

Authors:  Chenshu Xu; Xinkun Wang; Jeff L Staudinger
Journal:  Drug Metab Dispos       Date:  2009-04-09       Impact factor: 3.922

Review 7.  PXR antagonists and implication in drug metabolism.

Authors:  Sridhar Mani; Wei Dou; Matthew R Redinbo
Journal:  Drug Metab Rev       Date:  2013-02       Impact factor: 4.518

8.  Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice.

Authors:  Changcheng Zhou; Nakesha King; Kwan Y Chen; Jan L Breslow
Journal:  J Lipid Res       Date:  2009-05-12       Impact factor: 5.922

Review 9.  Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.

Authors:  Arunima Biswas; Sridhar Mani; Matthew R Redinbo; Matthew D Krasowski; Hao Li; Sean Ekins
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

10.  Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice.

Authors:  Robert N Helsley; Yipeng Sui; Ni Ai; Se-Hyung Park; William J Welsh; Changcheng Zhou
Journal:  Mol Pharmacol       Date:  2013-03-21       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.